Skip to content

Clinical and Therapeutic Characteristics of Geriatric Patients Hospitalized for Heart Failure (AGING HF Study (AGe and Heart Failure IN Geriatrics))

Clinical and Therapeutic Characteristics of Geriatric Patients Hospitalized for Heart Failure

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06377904
Acronym
AGING HF
Enrollment
810
Registered
2024-04-22
Start date
2024-04-30
Completion date
2028-04-30
Last updated
2024-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients Aged 75 and Over, Patients Hospitalized in Geriatrics for Heart Failure

Keywords

Heart failure, Geriatrics, AGE

Brief summary

This retrospective (between April 2020 and December 2023) then prospective (between January 2024 and August 2026), non-interventional cohort study has as its main objective to evaluate the clinical and therapeutic characteristics of patients aged 75 and over hospitalized in geriatrics for heart failure and also to evaluate the clinical characteristics and triggering factor(s) of acute heart failure.

Detailed description

Multicenter study, including patients aged 75 and over, hospitalized in geriatrics and having suffered heart failure in the geriatric wards of 3 centers. The following elements will be collected: * Demographic data * History (comorbidities) * Type of heart disease * Frailty criteria * Clinical signs of heart failure * Geriatric syndromes (falls, cognitive disorders, (MMSE) confusion, malnutrition, loss of autonomy (ADL, IADL), bedsores) * Biology available (CBC, ionogram, creatinine, NT pro BNP, BHC, troponin, TSH, HBA1C) * ECG and echocardiography data * Treatment on admission, during stay and on discharge * Mode of discharge and length of stay * Follow-up at 3, 6, 9 months and one year, through telephone calls with the patient, caregiver or attending physician. Questions will cover various aspects of health and quality of life, physical activity limitations, autonomy, symptoms, anxiety, depression, as well as neurocognitive status (using adapted questions).

Interventions

None listed

Sponsors

Gérond'if
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
75 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients aged 75 and over Hospitalized in a geriatric ward with heart failure No oral opposition from patient

Exclusion criteria

* Patient under 75 years of age Patient not wishing to participate in the study Subject under guardianship/curatorship/supervision of justice

Design outcomes

Primary

MeasureTime frameDescription
Evaluate the clinical and therapeutic characteristics of elderly patients hospitalized in geriatrics for heart failure36 monthsTo Evaluate the clinical and therapeutic characteristics of elderly patients hospitalized in geriatrics for heart failure with 80% power and 5% alpha risk and expressed as a percentage.

Secondary

MeasureTime frameDescription
Factors associated with patients hospitalization or rehospitalization12 monthsQuantitative data will be described as mean ± standard deviation. Qualitative variables will be expressed as percentages Statistical differences (hospitalized and/or deceased vs. non-rehospitalized and/or non-deceased patients) will be assessed using the Mann-Whitney U-test and Student's t-test for non-parametric and parametric continuous variables, respectively. Discrete variables will be normally distributed, and by the Mann-Whitney test for those not normally distributed. Survival curves will be drawn to analyze mortality and hospitalizations. Evaluated using the χ2 or Fisher test. Differences between groups will be assessed by ANOVA for the variables

Contacts

Primary ContactIsabelle DUFOUR
isabelle.dufour@gerondif.org+33 (01) 185 78 10 10
Backup ContactPrisca LUCAS, Project manager
prisca.lucas@gerondif.org+ 33 (01)85 78 10 10

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026